CHANGE IN RATINGS
was upgraded at Friedman, Billings Ramsey to Outperform. Sell-off has eliminated any takeover premium, and the stock could still see $40 if it remains independent.
downgraded at Friedman, Billings Ramseyfrom Outperform to Market Perform. $24 price target. Expect the company to be hit by a more negative economic outlook.
upgraded at Jefferies to Buy rating from Hold. FY 2008 EPS estimates rise to $1.38 from $1.35, while price target drops to $10.14 from $12.50.
downgraded at Wachovia to Market Perform from Outperform. Concerns rose following management's comments during a debt offering investor call that an equity offering was likely during the next 6-9 months.
downgraded at JP Morgan from Neutral to Overweight. Stock is up 24% over the past three days, and is already pricing in near-term margin gains.
upgraded at Jefferies to Hold rating from Under Perform. FY 2008 EPS estimates rise to $1.60 from $1.55, and price target lifts to $19 from $18.60.
downgraded at Wachovia to Market Perform. Second quarter operational results were lower than expected. Management lowered full year guidance due to slower than expected growth from their digitized New York City households. Estimates reduced.
downgraded at Merrill from Neutral to Sell. Company did not execute on its high potential exploration programs, and the stock is the most richly valued in the universe.
upgraded at JMP Securities from Market Perform to Outperform. $12 price target. Cost cutting is paying off, offsetting the effect of the recent revenue miss.
upgraded ay Merrill Lynch to Buy. Shares are down 27% this year. Short-term outlook appears positive with favorable resolution of Lexapro patent risk, possible share repurchases, and progression of pipeline. $43 price target.
Green Mountain Coffee
downgraded at Piper to a Market Perform rating as company laps Kuerig acquisition in current quarter and headline results may not impress as in the past.
initiated at Jefferies with Buy rating. Price target starts at $34 and FY2008 EPS estimates forecast at $1.59.
upgraded at Baird from Neutral to Outperform. $18 price target. Feel more comfortable about RGU trends, following the company's conference call.
downgraded at JMP Securities from Outperform to Market Perform. Stock pulled back after-hours and its growth potential may be less attractive in the current environment.
upgraded at Piper to an Outperform rating. Stock is trading at just 12.8X CY08 earnings. Target price is $29.
upgraded at Jefferies to Hold rating from Under Perform. FY 2008 EPS estimates rise to $2.25 from $2.00, and price target pops to $36 from $33.
upgraded at Suntrust Robinson Humphreyfrom Reduce to Neutral. Stock is down 50% since April, though sales growth could still remain low in the coming months.
upgraded at JP Morgan from Underweight to Neutral. Valuation call, as margins have reverted back to peak levels.
upgraded at Goldman Sachs to Neutral from Sell. Recent selloff has pushed shares below $50 target price. While competitive environment remains tough, see potential for some favorable seasonality and share buyback. Maintained $50 target.
upgraded at Goldman Sachs to Buy from Neutral based on valuation. Believe investors are underestimating earnings power driven by global infrastructure spending.
upgraded at Deutsche Bank to Buy. Shares have declined 18% from May yet the outlook remains strong, including sustained demand for core retirement practice and steady pipeline of deals in tech and human capital practices. $50 price target.
upgraded at Citigroup to Buy from Hold. Neuropathic pain now incorporated into model given the strong likelihood lead drug 512 will have clinical success. Price target raised to $58 from $42.
STOCK COMMENTS / EPS CHANGES
numbers raised at UBS. FY 2008 EPS estimates jump to $6.64 from $6.49, while price target holds at $78. Reiterates Neutral rating.
2007 estimates lowered at Credit Suisse to 59 cents from 65 cents. Company reported strong Q2 revenues but margins fell short of forecasts. Maintained $18 target price.
Dick's Sporting Goods
target price raised at Piper from $60 to $70 following meeting with management. Maintained Outperform rating.
numbers raised at UBS. FY 2008 EPS estimates upped to $1.24 from $1.22, while price target holds at $27. Reiterates Buy rating.